Yonhap News AgencyDoubao · 实盘不做把握 5/10不做原因:其他
北京时间·🕒 发布 15:38:12(首尔 16:38)·⟳ 抓取 15:41:24 +3m12s·⚡ 决策 10-21 15:44:27 +3m03s·6.2 天前
三星生物制剂Q3营收创纪录、营业利润超预期，并上调全年营收增速指引至20%
盘后正式业绩含多项增量利好（营业利润超预期、全年指引上调至20%上沿、220亿美元在手订单），方向明确且韩国次日开盘可执行；但7月Q2已预告争取区间上沿、10月初已有超预期前瞻，预期差被部分消化，故小仓参与并限制追高。
📄 原文Yonhap News Agency↗ 原文
(LEAD) Samsung Biologics Q3 net income down over 20 pct
(ATTN: CHANGES headline; ADDS additional info at bottom, photo) SEOUL, Oct. 21 (Yonhap) -- Samsung Biologics Co., the b…
不做 Samsung Biologics Co., Ltd.（207940.KS）
[契约校验:INVALID_PRICE] entry.limit_price: Input should be greater than 0 原交易逻辑:盘后Q3营业利润超预期+全年指引上调至20%，次日开盘博重定价
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
三星生物制剂Q3营收创纪录、营业利润6401亿韩元超预期，核心CDMO经营强劲，并将全年营收增速指引上调至20%上沿、在手订单220亿美元；净利润下滑系营业外因素。业绩盘后披露、次日韩国开盘前仍有窗口，小仓BUY_AT_OPEN并限制高开追入。
消息传播链
- 节点
关键理由
- 营业利润超预期+全年指引正式上调至20%上沿+220亿美元在手订单，核心CDMO需求与产能利用率持续验证
- 业绩在韩国收盘后发布、市场尚未交易，10月22日开盘存在对增量指引与超预期营业利润重定价的窗口
主要风险
- 7月Q2已表态争取指引上沿、10月初媒体已有超预期前瞻，部分利好可能已price-in，次日若大幅高开(>5%)易冲高回落
- 净利润同比-21.2%若被归因于汇兑损失等持续项或被市场放大解读，可能压制开盘情绪
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-06 · 影响 weakens
朝鲜日报10月6日前瞻虽指Q3盈利超预期，但因股本摊薄将目标价下调至195万韩元；净利润-21.2%为营业外项，构成开盘情绪与估值层面的反方，削弱但不否决做多逻辑
检索:삼성바이오로직스 3분기 순이익 하락 영업외 손실 target price lowered share dilution 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足+增量指引部分被7月表态提前消化，直接将仓位降至small、收紧追高至+5%、止盈保守
方向:无可用对齐先例，不据此假设涨幅
涨幅量级:行情/先例取价服务本轮连接失败，无法用真实日线校准幅度，tp取保守小档
形态:未能验证三星生物制剂历史盘后财报后见光死概率
工具执行结果 · 成功 3 · 降级 0 · 失败 2 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 33 ms
{"result": "search_processed_events:agent query=`207940 samsung biologics third-quarter 2026 results cdmo orders | samsung biologics q3 2026 earnings net profit guidance raised | 삼성바이오로직스 3분기 실적 가이던스 20%`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息 - stock_quote 失败 stock_tools HTTP · 22 ms
行情服务暂不可用；本次无法核验该标的价格和可执行条件。请基于其余证据继续判断并明确标注行情降级；不得仅因工具故障自动给出 AVOID 或 ENTER，也不得编造价位。 - web_search 成功 doubao_search · 1,736 ms
豆包搜索结果（原始查询:Samsung Biologics Q3 2026 earnings results operating profit consensus expectations guidance；API SearchType:web） - kb_search 失败 stock_tools HTTP · 62 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,839 ms
豆包搜索结果（原始查询:Samsung Biologics 3Q26 earnings beat forecast analyst consensus 영업이익 시장 기대；API SearchType:web）
原文全文
展开原文 · 1,412 字
(ATTN: CHANGES headline; ADDS additional info at bottom, photo)
SEOUL, Oct. 21 (Yonhap) -- Samsung Biologics Co., the biotech arm of Samsung Group, on Wednesday reported its third-quarter net profit of 391.1 billion won (US$295.2 million), down 21.2 percent from a year earlier.
The contract development and manufacturing organization (CDMO) service provider, which offers comprehensive development and manufacturing solutions, said in a regulatory filing that it posted 640.1 billion won in operating profit for the quarter, compared with 633.5 billion won a year ago.
Revenue rose 18.5 percent to 1.49 trillion won.
The company attributed its sales increase to full-scale operations at four plants in Songdo, just west of Seoul, a ramp-up in production at its fifth plant, as well as sales generated from its first U.S.-based biomanufacturing facility in Rockville, Maryland, acquired in March.
The company said it will continue to expand its contract development and manufacturing (CDMO) business, with cumulative contract orders for this year reaching US$22 billion.
It also raised the company's annual sales guidance this year to 20 percent, from the early estimate of 15 to 20 percent, citing stable growth of its production plants.
People walk outside the biomanufacturing facility of Samsung Biologics Co. in Songdo, west of Seoul, in this file photo taken May 6, 2026. (Yonhap)
fairydust@yna.co.kr
(END)
SEOUL, Oct. 21 (Yonhap) -- Samsung Biologics Co., the biotech arm of Samsung Group, on Wednesday reported its third-quarter net profit of 391.1 billion won (US$295.2 million), down 21.2 percent from a year earlier.
The contract development and manufacturing organization (CDMO) service provider, which offers comprehensive development and manufacturing solutions, said in a regulatory filing that it posted 640.1 billion won in operating profit for the quarter, compared with 633.5 billion won a year ago.
Revenue rose 18.5 percent to 1.49 trillion won.
The company attributed its sales increase to full-scale operations at four plants in Songdo, just west of Seoul, a ramp-up in production at its fifth plant, as well as sales generated from its first U.S.-based biomanufacturing facility in Rockville, Maryland, acquired in March.
The company said it will continue to expand its contract development and manufacturing (CDMO) business, with cumulative contract orders for this year reaching US$22 billion.
It also raised the company's annual sales guidance this year to 20 percent, from the early estimate of 15 to 20 percent, citing stable growth of its production plants.
People walk outside the biomanufacturing facility of Samsung Biologics Co. in Songdo, west of Seoul, in this file photo taken May 6, 2026. (Yonhap)
fairydust@yna.co.kr
(END)
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8fbb42a1ec· 2026-10-21 15:44 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前